Listing 1 - 5 of 5 |
Sort by
|
Choose an application
Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.
Medicine --- MSI2 --- OSCC --- oral cancer --- musashi 2 --- prognosis --- N-cadherin --- EMT --- breast cancer --- new metastasis --- eribulin --- blood --- biomarker --- bladder cancer --- immune checkpoint inhibitor --- CD8+ T effector cells --- microRNA --- biomarkers --- head and neck cancer --- laryngeal cancer --- prediction --- metastasis --- lifestyle habit --- chemo-/radio resistance --- therapeutic target --- AKT --- AR --- castration-resistant prostate cancer (CRPC) --- MAPK --- mTOR --- PI3K --- prostate cancer --- therapeutic resistance --- WNT --- miRNA --- melanoma --- melanoma resistance to MAPK/MEK inhibitors --- resistance to immune checkpoint inhibitors --- TNBC --- BRCA1/2 --- HRR --- PDL1 --- TILs --- PI3KCA --- PTEN --- CTCs --- CSC --- pancreatic cancer --- K-RAS oncogene --- oncogene dependency --- targeted therapies --- genomic mutations --- transcriptomics --- metabolomics --- selenoproteins --- cancer --- HUB nodes --- major histocompatibility complex (MHC) --- human leukocyte antigen (HLA) --- antigen processing machinery (APM) molecules --- carcinogenesis --- tumor predisposition --- cancer immunotherapy --- pheochromocytoma --- paraganglioma --- head and neck neoplasms --- head and neck tumors --- genetic syndromes --- mutations --- hyperglycemia --- cardioncology --- nivolumab --- cytokines --- cardiotoxicity --- acetyltransferase --- cancer prognosis --- NAA10 --- n/a
Choose an application
Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.
Medicine --- MSI2 --- OSCC --- oral cancer --- musashi 2 --- prognosis --- N-cadherin --- EMT --- breast cancer --- new metastasis --- eribulin --- blood --- biomarker --- bladder cancer --- immune checkpoint inhibitor --- CD8+ T effector cells --- microRNA --- biomarkers --- head and neck cancer --- laryngeal cancer --- prediction --- metastasis --- lifestyle habit --- chemo-/radio resistance --- therapeutic target --- AKT --- AR --- castration-resistant prostate cancer (CRPC) --- MAPK --- mTOR --- PI3K --- prostate cancer --- therapeutic resistance --- WNT --- miRNA --- melanoma --- melanoma resistance to MAPK/MEK inhibitors --- resistance to immune checkpoint inhibitors --- TNBC --- BRCA1/2 --- HRR --- PDL1 --- TILs --- PI3KCA --- PTEN --- CTCs --- CSC --- pancreatic cancer --- K-RAS oncogene --- oncogene dependency --- targeted therapies --- genomic mutations --- transcriptomics --- metabolomics --- selenoproteins --- cancer --- HUB nodes --- major histocompatibility complex (MHC) --- human leukocyte antigen (HLA) --- antigen processing machinery (APM) molecules --- carcinogenesis --- tumor predisposition --- cancer immunotherapy --- pheochromocytoma --- paraganglioma --- head and neck neoplasms --- head and neck tumors --- genetic syndromes --- mutations --- hyperglycemia --- cardioncology --- nivolumab --- cytokines --- cardiotoxicity --- acetyltransferase --- cancer prognosis --- NAA10 --- n/a
Choose an application
Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.
MSI2 --- OSCC --- oral cancer --- musashi 2 --- prognosis --- N-cadherin --- EMT --- breast cancer --- new metastasis --- eribulin --- blood --- biomarker --- bladder cancer --- immune checkpoint inhibitor --- CD8+ T effector cells --- microRNA --- biomarkers --- head and neck cancer --- laryngeal cancer --- prediction --- metastasis --- lifestyle habit --- chemo-/radio resistance --- therapeutic target --- AKT --- AR --- castration-resistant prostate cancer (CRPC) --- MAPK --- mTOR --- PI3K --- prostate cancer --- therapeutic resistance --- WNT --- miRNA --- melanoma --- melanoma resistance to MAPK/MEK inhibitors --- resistance to immune checkpoint inhibitors --- TNBC --- BRCA1/2 --- HRR --- PDL1 --- TILs --- PI3KCA --- PTEN --- CTCs --- CSC --- pancreatic cancer --- K-RAS oncogene --- oncogene dependency --- targeted therapies --- genomic mutations --- transcriptomics --- metabolomics --- selenoproteins --- cancer --- HUB nodes --- major histocompatibility complex (MHC) --- human leukocyte antigen (HLA) --- antigen processing machinery (APM) molecules --- carcinogenesis --- tumor predisposition --- cancer immunotherapy --- pheochromocytoma --- paraganglioma --- head and neck neoplasms --- head and neck tumors --- genetic syndromes --- mutations --- hyperglycemia --- cardioncology --- nivolumab --- cytokines --- cardiotoxicity --- acetyltransferase --- cancer prognosis --- NAA10 --- n/a
Choose an application
This book comprises proceedings from the Third International Conference on Advances in Nutrition and Cancer, held in Naples in May 2012. This highly multidisciplinary meeting analyzed “nutrition and cancer” from different perspectives and on the basis of distinct and up-to-date experimental approaches. Knowledge on the relation between lifestyle, diet, and cancer is explored in a number of contributions, and the role of dietary intervention in cancer patients is discussed. Issues of vital interest to the research community, such as epidemiological and experimental oncology (genetics, epigenetics, and the mechanisms of action of natural compounds in the diet), receive detailed consideration. A further key topic is the emerging molecular technologies (the “omics”) that can cast light on the interplay between nutrition and human malignancies. Chapters take the form of reviews that include sections presenting expert opinions. Advances in Nutrition and Cancer will be an invaluable source of topical information for all researchers and clinicians with an interest in this field.
Human biochemistry --- Hygiene. Public health. Protection --- Oncology. Neoplasms --- Epidemiology --- Human genetics --- Pathology of the metabolism --- medische biochemie --- preventieve gezondheidszorg --- medische genetica --- biochemie --- genetica --- gezondheidspromotie --- metabolische ziekten --- oncologie --- epidemiologie --- moleculaire biologie
Choose an application
This book comprises proceedings from the Third International Conference on Advances in Nutrition and Cancer, held in Naples in May 2012. This highly multidisciplinary meeting analyzed “nutrition and cancer” from different perspectives and on the basis of distinct and up-to-date experimental approaches. Knowledge on the relation between lifestyle, diet, and cancer is explored in a number of contributions, and the role of dietary intervention in cancer patients is discussed. Issues of vital interest to the research community, such as epidemiological and experimental oncology (genetics, epigenetics, and the mechanisms of action of natural compounds in the diet), receive detailed consideration. A further key topic is the emerging molecular technologies (the “omics”) that can cast light on the interplay between nutrition and human malignancies. Chapters take the form of reviews that include sections presenting expert opinions. Advances in Nutrition and Cancer will be an invaluable source of topical information for all researchers and clinicians with an interest in this field.
Cancer --- Nutritional aspects. --- Diet therapy. --- Medicine. --- Human genetics. --- Health promotion. --- Metabolic diseases. --- Oncology. --- Epidemiology. --- Medicine & Public Health. --- Health Promotion and Disease Prevention. --- Biomedicine general. --- Human Genetics. --- Metabolic Diseases. --- Nutritional aspects --- Treatment --- Oncology . --- Disorders of metabolism --- Metabolic diseases --- Metabolic disorders --- Metabolism, Disorders of --- Diseases --- Genetics --- Heredity, Human --- Human biology --- Physical anthropology --- Public health --- Clinical sciences --- Medical profession --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Tumors --- Health Workforce --- Biomedicine, general. --- Health promotion programs --- Health promotion services --- Promotion of health --- Wellness programs --- Preventive health services --- Health education --- Medicine, Preventive. --- Medicine --- Biology --- Medical genetics. --- Diseases. --- Biomedical Research. --- Medical Genetics. --- Research. --- Human beings --- Illness --- Illnesses --- Morbidity --- Sickness --- Sicknesses --- Epidemiology --- Health --- Sick --- Clinical genetics --- Heredity of disease --- Human genetics --- Genetic disorders --- Biological research --- Biomedical research --- Disease prevention --- Prevention of disease --- Preventive medicine --- Preventive medicine physicians --- Genetic aspects --- Prevention
Listing 1 - 5 of 5 |
Sort by
|